Cargando…

Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83

CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinser, Elisabeth, Lechmann, Matthias, Golka, Antje, Lutz, Manfred B., Steinkasserer, Alexander
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211980/
https://www.ncbi.nlm.nih.gov/pubmed/15289503
http://dx.doi.org/10.1084/jem.20030973
_version_ 1782148596653621248
author Zinser, Elisabeth
Lechmann, Matthias
Golka, Antje
Lutz, Manfred B.
Steinkasserer, Alexander
author_facet Zinser, Elisabeth
Lechmann, Matthias
Golka, Antje
Lutz, Manfred B.
Steinkasserer, Alexander
author_sort Zinser, Elisabeth
collection PubMed
description CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even when the EAE was induced a second time, CD83-treated mice were protected, indicating a long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in different therapeutic settings. Most important, even when the treatment was delayed until the disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition, also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune disorders in vivo.
format Text
id pubmed-2211980
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22119802008-03-11 Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 Zinser, Elisabeth Lechmann, Matthias Golka, Antje Lutz, Manfred B. Steinkasserer, Alexander J Exp Med Article CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even when the EAE was induced a second time, CD83-treated mice were protected, indicating a long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in different therapeutic settings. Most important, even when the treatment was delayed until the disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition, also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune disorders in vivo. The Rockefeller University Press 2004-08-02 /pmc/articles/PMC2211980/ /pubmed/15289503 http://dx.doi.org/10.1084/jem.20030973 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Zinser, Elisabeth
Lechmann, Matthias
Golka, Antje
Lutz, Manfred B.
Steinkasserer, Alexander
Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title_full Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title_fullStr Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title_full_unstemmed Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title_short Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
title_sort prevention and treatment of experimental autoimmune encephalomyelitis by soluble cd83
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211980/
https://www.ncbi.nlm.nih.gov/pubmed/15289503
http://dx.doi.org/10.1084/jem.20030973
work_keys_str_mv AT zinserelisabeth preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83
AT lechmannmatthias preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83
AT golkaantje preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83
AT lutzmanfredb preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83
AT steinkassereralexander preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83